Top

Journal of Neuroinflammation

Published in:

01-12-2020 | Glioblastoma | Research

Immunological classification of gliomas based on immunogenomic profiling

Authors: Qiushi Feng, Lin Li, Mengyuan Li, Xiaosheng Wang

Published in: Journal of Neuroinflammation | Issue 1/2020

Abstract

Background

Gliomas are heterogeneous in the tumor immune microenvironment (TIM). However, a classification of gliomas based on immunogenomic profiling remains lacking.

Methods

We hierarchically clustered gliomas based on the enrichment levels of 28 immune cells in the TIM in five datasets and obtained three clusters: immunity-high, immunity-medium, and immunity-low.

Results

Glioblastomas were mainly distributed in immunity-high and immunity-medium, while lower-grade gliomas were distributed in all the three subtypes and predominated in immunity-low. Immunity-low displayed a better survival than other subtypes, indicating a negative correlation between immune infiltration and survival prognosis in gliomas. IDH mutations had a negative correlation with glioma immunity. Immunity-high had higher tumor stemness and epithelial-mesenchymal transition scores and included more high-grade tumors than immunity-low, suggesting that elevated immunity is associated with tumor progression in gliomas. Immunity-high had higher tumor mutation burden and more frequent somatic copy number alterations, suggesting a positive association between tumor immunity and genomic instability in gliomas.

Conclusions

The identification of immune-specific glioma subtypes has potential clinical implications for the immunotherapy of gliomas.

Available only for authorised users

Bacolod MD, et al. Immune infiltration, glioma stratification, and therapeutic implications. Transl Cancer Res. 2016;5(Suppl 4):S652–6.PubMedCrossRef

Cancer Genome Atlas Research, N, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481–98.CrossRef

Verhaak RG, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110.PubMedPubMedCentralCrossRef

Doucette T, et al. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res. 2013;1(2):112–22.PubMedCrossRef

Wu F, et al. Classification of diffuse lower-grade glioma based on immunological profiling. Mol Oncol . 2020;14(9):2081–95.

Klemm F, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell. 2020;181(7):1643–60 e17.PubMedCrossRefPubMedCentral

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–5.PubMedPubMedCentralCrossRef

June CH, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5.PubMedCrossRef

Del Paggio JC. Cancer immunotherapy and the value of cure. Nat Rev Clin Oncol. 2018;15(5):268–70.

10.

Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–56.PubMedCrossRef

11.

Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.PubMedPubMedCentralCrossRef

12.

Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8.PubMedPubMedCentralCrossRef

13.

Haanen J. Converting cold into hot tumors by combining immunotherapies. Cell. 2017;170(6):1055–6.PubMedCrossRef

14.

He Y, et al. Classification of triple-negative breast cancers based on immunogenomic profiling. J Exp Clin Cancer Res. 2018;37(1):327.PubMedPubMedCentralCrossRef

15.

Xu F, et al. Analysis of lung adenocarcinoma subtypes based on immune signatures identifies clinical implications for cancer therapy. Mol Ther Oncolytics. 2020;17:241–9.PubMedPubMedCentralCrossRef

16.

Gravendeel LA, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009;69(23):9065–72.PubMedCrossRef

17.

Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.PubMedPubMedCentralCrossRef

18.

Charoentong P, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–62.PubMedCrossRef

19.

Yoshihara K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.PubMedCrossRef

20.

Kanehisa M, et al. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353–61.PubMedCrossRef

21.

Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.PubMedPubMedCentralCrossRef

22.

Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.PubMedPubMedCentralCrossRef

23.

Mayakonda A, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56.PubMedPubMedCentralCrossRef

24.

Mermel CH, et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.PubMedPubMedCentralCrossRef

25.

Breiman L. Random Forests. Machine Learning. 2001;45(1):5–32.CrossRef

26.

Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statistical Society B. 1995;57:289–300.

27.

Liu Z, et al. A comprehensive immunologic portrait of triple-negative breast cancer. Transl Oncol. 2018;11(2):311–29.PubMedPubMedCentralCrossRef

28.

Burstein MD, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–98.PubMedCrossRef

29.

Jezequel P, et al. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res. 2015;17:43.PubMedPubMedCentralCrossRef

30.

Jiang Z, et al. Immunogenomics analysis reveals that TP53 mutations inhibit tumor immunity in gastric cancer. Transl Oncol. 2018;11(5):1171–87.PubMedPubMedCentralCrossRef

31.

Lyu H, et al. Correlate the TP53 mutation and the HRAS mutation with immune signatures in head and neck squamous cell cancer. Comput Struct Biotechnol J. 2019;17:1020–30.PubMedPubMedCentralCrossRef

32.

Jiang, S., et al., Cell cycle activity correlates with increased anti-tumor immunity in diverse cancers. Clin Transl Med, 2020.

33.

Jiang, Z., et al., Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment. EBioMedicine, 2019.CrossRef

34.

Iakovleva NV, Gorbushin AM, Storey KB. Modulation of mitogen-activated protein kinases (MAPK) activity in response to different immune stimuli in haemocytes of the common periwinkle Littorina littorea. Fish Shellfish Immunol. 2006;21(3):315–24.PubMedCrossRef

35.

Le Menn G, Neels JG. Regulation of Immune Cell Function by PPARs and the Connection with Metabolic and Neurodegenerative Diseases. International journal of molecular sciences. 2018;19(6):1575.

36.

Rooney MS, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1-2):48–61.PubMedPubMedCentralCrossRef

37.

Davoli T, et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science (New York, N.Y.). 2017;355(6322):eaaf8399.

38.

Miranda A. et al. Cancer stemness, intratumoral heterogeneity, and immune response across cancers. 2019;116(18):9020–9.

39.

Zhu C, et al. Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients. J Transl Med. 2019;17(1):109.PubMedPubMedCentralCrossRef

40.

Yan H, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73.PubMedPubMedCentralCrossRef

41.

Pombo Antunes AR, et al. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. eLife. 2020;9:e52176.

42.

Alsaab HO, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.PubMedPubMedCentralCrossRef

43.

Amankulor NM, et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 2017;31(8):774–86.PubMedPubMedCentralCrossRef

44.

Berghoff AS, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol. 2017;19(11):1460–8.PubMedPubMedCentralCrossRef

45.

Thorsson V, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–30 e14.PubMedPubMedCentralCrossRef

46.

Wang A, et al. Opposing effects of fasting metabolism on tissue tolerance in bacterial and viral inflammation. Cell. 2016;166(6):1512–25 e12.PubMedPubMedCentralCrossRef

47.

Marinari E, et al. Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma. Oncoimmunology. 2020;9(1):1779990.PubMedPubMedCentralCrossRef

Title: Immunological classification of gliomas based on immunogenomic profiling
Authors: Qiushi Feng
Lin Li
Mengyuan Li
Xiaosheng Wang
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Glioblastoma
Glioma
Glioma
Glioblastoma
Glioblastoma
Glioma
Published in: Journal of Neuroinflammation / Issue 1/2020
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/s12974-020-02030-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Immunological classification of gliomas based on immunogenomic profiling

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Transcriptomic profiling of microglia and astrocytes throughout aging

A1 reactive astrocytes and a loss of TREM2 are associated with an early stage of pathology in a mouse model of cerebral amyloid angiopathy

Inhibition of formyl peptide receptors improves the outcome in a mouse model of Alzheimer disease

Astrocytes from cortex and striatum show differential responses to mitochondrial toxin and BDNF: implications for protection of striatal neurons expressing mutant huntingtin

Deficiency of Nrf2 exacerbates white matter damage and microglia/macrophage levels in a mouse model of vascular cognitive impairment

NT-4 attenuates neuroinflammation via TrkB/PI3K/FoxO1 pathway after germinal matrix hemorrhage in neonatal rats